Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 19, 2024, titled "Zydus and Synthonenter into an exclusive licensing and supply agreement for Palbociclib Tablets (genericversion of IBRANCE��) for the US market".
Press Release Jan 19 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced an exclusive licensing and supply agreement with Synthon for Palbociclib Tablets, a generic version of IBRANCE, intended for the US market. Under this agreement, Synthon will handle regulatory approval and manufacturing, while Zydus will focus on commercialization. This partnership aims to address significant unmet medical needs in oncology for patients in the US.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 17 2024
- Press Release Dec 22 2023
- Press Release Dec 16 2023
- Press Release Dec 15 2023
- Press Release Dec 14 2023
Later from Zydus Lifesciences
- Press Release Jan 25 2024
- Zydus Lifesciences Limited Press Release Jan 30 2024
- Press Release Feb 08 2024
- Press Release Feb 09 2024
- Press Release Feb 16 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences